{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T21:03:31Z","timestamp":1780347811441,"version":"3.54.1"},"reference-count":173,"publisher":"Elsevier","isbn-type":[{"value":"9780443429934","type":"print"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/bs.acc.2025.01.006","type":"book-chapter","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T20:24:52Z","timestamp":1742243092000},"page":"31-71","source":"Crossref","is-referenced-by-count":3,"title":["Advances in neurofilament light chain analysis"],"prefix":"10.1016","author":[{"given":"Arejas J.","family":"Uzgiris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lance A.","family":"Ladic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia X.","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/bs.acc.2025.01.006_bib1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000132421","article-title":"The human neurofilament gene (nefl) is located on the short arm of chromosome 8","volume":"45","author":"Hurst","year":"1987","journal-title":"Cytogenet. Cell Genet."},{"key":"10.1016\/bs.acc.2025.01.006_bib2","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1046\/j.1471-4159.1996.67052013.x","article-title":"Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in csf","volume":"67","author":"Rosengren","year":"1996","journal-title":"J. Neurochem."},{"key":"10.1016\/bs.acc.2025.01.006_bib3","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcad067","article-title":"Uman-type neurofilament light antibodies are effective reagents for the imaging of neurodegeneration","volume":"5","author":"Shaw","year":"2023","journal-title":"Brain Commun."},{"key":"10.1016\/bs.acc.2025.01.006_bib4","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcac045","article-title":"A map of neurofilament light chain species in brain and cerebrospinal fluid and alterations in alzheimer\u2019s disease","volume":"4","author":"Budelier","year":"2022","journal-title":"Brain Commun."},{"key":"10.1016\/bs.acc.2025.01.006_bib5","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcac070","article-title":"Neurofilament light chain: defining the analyte","volume":"4","author":"Leckey","year":"2022","journal-title":"Brain Commun."},{"key":"10.1016\/bs.acc.2025.01.006_bib6","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1089\/15368590252917647","article-title":"Monoclonal antibodies selective for low molecular weight neurofilaments","volume":"21","author":"Norgren","year":"2002","journal-title":"Hybrid Hybridomics"},{"key":"10.1016\/bs.acc.2025.01.006_bib7","unstructured":"Https:\/\/www.Quanterix.Com\/simoa-assay-kits\/nf-light\/ (accessed October 9, 2024)."},{"key":"10.1016\/bs.acc.2025.01.006_bib8","unstructured":"Https:\/\/www.Siemens-healthineers.Com\/press\/releases\/neurofilament-light-chain-multiple-sclerosis (accessed October 9, 2024)."},{"key":"10.1016\/bs.acc.2025.01.006_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.935382","article-title":"Development of a highly sensitive neurofilament light chain assay on an automated immunoassay platform","volume":"13","author":"Lee","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/bs.acc.2025.01.006_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ceb.2023.102266","article-title":"Stability dynamics of neurofilament and gfap networks and protein fragments","volume":"85","author":"Phillips","year":"2023","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/bs.acc.2025.01.006_bib11","article-title":"The tail domain of neurofilament light chain accumulates in neuronal nuclei during oxidative injury","author":"Arsic","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/bs.acc.2025.01.006_bib12","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S1474-4422(24)00038-3","article-title":"Global, regional, and national burden of disorders affecting the nervous system: a systematic analysis for the global burden of disease study 2021","volume":"23","author":"Collaborators","year":"2024","journal-title":"Lancet Neurol."},{"key":"10.1016\/bs.acc.2025.01.006_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101580","article-title":"Global and regional projections of the economic burden of alzheimer\u2019s disease and related dementias from 2019 to 2050: a value of statistical life approach","volume":"51","author":"Nandi","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/bs.acc.2025.01.006_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/s41582-024-00955-x","article-title":"Neurofilaments as biomarkers in neurological disorders \u2013 towards clinical application","author":"Khalil","year":"2024","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/bs.acc.2025.01.006_bib15","article-title":"Plasma neurofilament light protein correlates with diffusion tensor imaging metrics in frontotemporal dementia","volume":"15","author":"Nicola","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/bs.acc.2025.01.006_bib16","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13195-018-0404-9","article-title":"Plasma neurofilament light as a potential biomarker of neurodegeneration in alzheimer\u2019s disease","volume":"10","author":"Lewczuk","year":"2018","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/bs.acc.2025.01.006_bib17","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","article-title":"Neurofilament light chain as a biomarker in neurological disorders","volume":"90","author":"Gaetani","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/bs.acc.2025.01.006_bib18","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1474-4422(22)00009-6","article-title":"Nf, Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study","volume":"21","author":"Benkert","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/bs.acc.2025.01.006_bib19","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000009559","article-title":"Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for als","volume":"95","author":"Benatar","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/bs.acc.2025.01.006_bib20","doi-asserted-by":"crossref","DOI":"10.1002\/ana.27054","article-title":"Population-based evidence for the use of serum neurofilaments as individual diagnostic and prognostic biomarkers in amyotrophic lateral sclerosis","author":"Witzel","year":"2024","journal-title":"Ann. Neurol."},{"key":"10.1016\/bs.acc.2025.01.006_bib21","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1038\/s41467-021-23620-z","article-title":"A multicentre validation study of the diagnostic value of plasma neurofilament light","volume":"12","author":"Ashton","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/bs.acc.2025.01.006_bib22","doi-asserted-by":"crossref","first-page":"36791","DOI":"10.1038\/srep36791","article-title":"Serum neurofilament light protein predicts clinical outcome in traumatic brain injury","volume":"6","author":"Shahim","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/bs.acc.2025.01.006_bib23","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3389\/fneur.2020.00448","article-title":"Acute neurofilament light chain plasma levels correlate with stroke severity and clinical outcome in ischemic stroke patients","volume":"11","author":"Nielsen","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/bs.acc.2025.01.006_bib24","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/14737159.2017.1341313","article-title":"Neurofilament light chain protein as a marker of neuronal injury: review of its use in hiv-1 infection and reference values for hiv-negative controls","volume":"17","author":"Yilmaz","year":"2017","journal-title":"Expert Rev. Mol. Diagn."},{"key":"10.1016\/bs.acc.2025.01.006_bib25","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1007\/s00415-023-11785-0","article-title":"Neurofilament light chain and cardiac mibg uptake as predictors for phenoconversion in isolated rem sleep behavior disorder","volume":"270","author":"Park","year":"2023","journal-title":"J. Neurol."},{"key":"10.1016\/bs.acc.2025.01.006_bib26","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3233\/JPD-223519","article-title":"Neurofilament light protein predicts disease progression in idiopathic rem sleep behavior disorder","volume":"13","author":"Zhang","year":"2023","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/bs.acc.2025.01.006_bib27","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/ijnp\/pyab068","article-title":"Neurofilament light chain is a novel biomarker for major depression and related executive dysfunction","volume":"25","author":"Chen","year":"2022","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/bs.acc.2025.01.006_bib28","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/brain\/awac328","article-title":"The multifaceted role of neurofilament light chain protein in non-primary neurological diseases","volume":"146","author":"Abu-Rumeileh","year":"2023","journal-title":"Brain"},{"key":"10.1016\/bs.acc.2025.01.006_bib29","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41398-018-0194-7","article-title":"Neurofilament light interaction with glun1 modulates neurotransmission and schizophrenia-associated behaviors","volume":"8","author":"Yuan","year":"2018","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/bs.acc.2025.01.006_bib30","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3988\/jcn.2022.0340","article-title":"Normative values for serum neurofilament light chain in us adults","volume":"20","author":"Beltran","year":"2024","journal-title":"J. Clin. Neurol."},{"key":"10.1016\/bs.acc.2025.01.006_bib31","doi-asserted-by":"crossref","DOI":"10.1002\/alz.080275","article-title":"A finger prick collection method for detecting blood biomarkers of neurodegeneration \u2013 a pilot study (drop\u2010ad)","volume":"19","author":"Huber","year":"2023","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"10.1016\/bs.acc.2025.01.006_bib32","article-title":"Validation of remote collection and quantification of blood neurofilament light in neurological diseases","author":"Coleman","year":"2023","journal-title":"medRxiv"},{"key":"10.1016\/bs.acc.2025.01.006_bib33","article-title":"Neurofilament light regulates axon caliber, synaptic activity, and organelle trafficking in cultured human motor neurons","volume":"9","author":"Sainio","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/bs.acc.2025.01.006_bib34","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/0022-2836(81)90011-5","article-title":"Self-assembly in vitro of the 68,000 molecular weight component of the mammalian neurofilament triplet proteins into intermediate-sized filaments","volume":"151","author":"Geisler","year":"1981","journal-title":"J. Mol. Biol."},{"key":"10.1016\/bs.acc.2025.01.006_bib35","doi-asserted-by":"crossref","first-page":"8501","DOI":"10.1523\/JNEUROSCI.1081-12.2012","article-title":"Peripherin is a subunit of peripheral nerve neurofilaments: implications for differential vulnerability of cns and peripheral nervous system axons","volume":"32","author":"Yuan","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/bs.acc.2025.01.006_bib36","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00401-004-0882-7","article-title":"Alpha-internexin aggregates are abundant in neuronal intermediate filament inclusion disease (nifid) but rare in other neurodegenerative diseases","volume":"108","author":"Cairns","year":"2004","journal-title":"Acta Neuropathol."},{"key":"10.1016\/bs.acc.2025.01.006_bib37","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/1531-8249(20010201)49:2<245::AID-ANA45>3.0.CO;2-A","article-title":"Further evidence that neurofilament light chain gene mutations can cause charcot-marie-tooth disease type 2e","volume":"49","author":"De Jonghe","year":"2001","journal-title":"Ann. Neurol."},{"key":"10.1016\/bs.acc.2025.01.006_bib38","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1046\/j.1529-8027.2002.02028.x","article-title":"Identification of novel sequence variants in the neurofilament-light gene in a japanese population: analysis of charcot-marie-tooth disease patients and normal individuals","volume":"7","author":"Yoshihara","year":"2002","journal-title":"J. Peripher. Nerv. Syst."},{"key":"10.1016\/bs.acc.2025.01.006_bib39","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1086\/302962","article-title":"A new variant of charcot-marie-tooth disease type 2 is probably the result of a mutation in the neurofilament-light gene","volume":"67","author":"Mersiyanova","year":"2000","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/bs.acc.2025.01.006_bib40","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0304-3940(03)00100-9","article-title":"Patients with a novel neurofilamentopathy: dementia with neurofilament inclusions","volume":"341","author":"Cairns","year":"2003","journal-title":"Neurosci. Lett."},{"key":"10.1016\/bs.acc.2025.01.006_bib41","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.nmd.2003.10.003","article-title":"The novel neurofilament light (nefl) mutation glu397lys is associated with a clinically and morphologically heterogeneous type of charcot-marie-tooth neuropathy","volume":"14","author":"Zuchner","year":"2004","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/bs.acc.2025.01.006_bib42","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1101\/cshperspect.a018242","article-title":"Intermediate filaments: structure and assembly","volume":"8","author":"Herrmann","year":"2016","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/bs.acc.2025.01.006_bib43","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1073\/pnas.2102176118","article-title":"Assembly of NfL and desmin intermediate filaments: headed in the right direction","volume":"118","author":"Faridounnia","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.acc.2025.01.006_bib44","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1073\/pnas.2022121118","article-title":"Transiently structured head domains control intermediate filament assembly","volume":"118","author":"Zhou","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.acc.2025.01.006_bib45","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0006-8993(03)03219-0","article-title":"Elevated neurofilament levels in neurological diseases","volume":"987","author":"Norgren","year":"2003","journal-title":"Brain Res."},{"key":"10.1016\/bs.acc.2025.01.006_bib46","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1016\/j.yexcr.2007.03.011","article-title":"New movements in neurofilament transport, turnover and disease","volume":"313","author":"Barry","year":"2007","journal-title":"Exp. Cell Res."},{"key":"10.1016\/bs.acc.2025.01.006_bib47","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1523\/JNEUROSCI.3742-14.2015","article-title":"Biomarkers of traumatic injury are transported from brain to blood via the glymphatic system","volume":"35","author":"Plog","year":"2015","journal-title":"J. Neurosci."},{"key":"10.1016\/bs.acc.2025.01.006_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.668606","article-title":"A kinetic model for blood biomarker levels after mild traumatic brain injury","volume":"12","author":"Azizi","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/bs.acc.2025.01.006_bib49","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3389\/fneur.2017.00300","article-title":"Serial sampling of serum protein biomarkers for monitoring human traumatic brain injury dynamics: a systematic review","volume":"8","author":"Thelin","year":"2017","journal-title":"Front. Neurol."},{"key":"10.1016\/bs.acc.2025.01.006_bib50","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.msard.2019.07.025","article-title":"Cerebrospinal fluid neurofilament light chain predicts disease activity after the first demyelinating event suggestive of multiple sclerosis","volume":"35","author":"Gaetani","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/bs.acc.2025.01.006_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0075091","article-title":"Increased neurofilament light chain blood levels in neurodegenerative neurological diseases","volume":"8","author":"Gaiottino","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/bs.acc.2025.01.006_bib52","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41582-021-00616-3","article-title":"Blood gfap as an emerging biomarker in brain and spinal cord disorders","volume":"18","author":"Abdelhak","year":"2022","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/bs.acc.2025.01.006_bib53","doi-asserted-by":"crossref","DOI":"10.1002\/ams2.622","article-title":"Thorough overview of ubiquitin c-terminal hydrolase-l1 and glial fibrillary acidic protein as tandem biomarkers recently cleared by us food and drug administration for the evaluation of intracranial injuries among patients with traumatic brain injury","volume":"8","author":"Wang","year":"2021","journal-title":"Acute Med. Surg."},{"key":"10.1016\/bs.acc.2025.01.006_bib54","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1093\/brain\/awac407","article-title":"Brain-derived tau: a novel blood-based biomarker for alzheimer\u2019s disease-type neurodegeneration","volume":"146","author":"Gonzalez-Ortiz","year":"2023","journal-title":"Brain"},{"key":"10.1016\/bs.acc.2025.01.006_bib55","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000009985","article-title":"Time course and diagnostic utility of NfL, tau, gfap, and uch-l1 in subacute and chronic tbi","volume":"95","author":"Shahim","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/bs.acc.2025.01.006_bib56","unstructured":"Https:\/\/www.Umandiagnostics.Se\/cms\/products\/ (accessed october 9, 2024)."},{"key":"10.1016\/bs.acc.2025.01.006_bib57","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1212\/01.WNL.0000142988.49341.D1","article-title":"Neurofilament and glial fibrillary acidic protein in multiple sclerosis","volume":"63","author":"Norgren","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/bs.acc.2025.01.006_bib58","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.brainresbull.2005.06.031","article-title":"Cerebrospinal fluid levels of neurofilament light in chronic experimental autoimmune encephalomyelitis","volume":"67","author":"Norgren","year":"2005","journal-title":"Brain Res. Bull."},{"key":"10.1016\/bs.acc.2025.01.006_bib59","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/ana.26446","article-title":"Contributors to serum NfL levels in people without neurologic disease","volume":"92","author":"Fitzgerald","year":"2022","journal-title":"Ann. Neurol."},{"key":"10.1016\/bs.acc.2025.01.006_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103676","article-title":"Type of serum collection tube does not impact neurofilament light chain levels","volume":"59","author":"Sotirchos","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/bs.acc.2025.01.006_bib61","unstructured":"Https:\/\/www.Siemens-healthineers.Com\/en-us\/press-room\/press-releases\/snfl-breakthrough-device-designation (accessed october 9, 2024)."},{"key":"10.1016\/bs.acc.2025.01.006_bib62","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/acn3.51704","article-title":"Associations of SNfL with clinico-radiological measures in a large ms population","volume":"10","author":"Sotirchos","year":"2023","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/bs.acc.2025.01.006_bib63","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1515\/cclm-2015-1195","article-title":"Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: Elisa, electrochemiluminescence immunoassay and simoa","volume":"54","author":"Kuhle","year":"2016","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/bs.acc.2025.01.006_bib64","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nbt.1641","article-title":"Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations","volume":"28","author":"Rissin","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/bs.acc.2025.01.006_bib65","article-title":"Serum NfL levels in the first five years predict 10-year thalamic fraction in patients with ms","volume":"8","author":"Lokhande","year":"2022","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/bs.acc.2025.01.006_bib66","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211001977","article-title":"Implications of extreme serum neurofilament light chain levels for the management of patients with relapsing multiple sclerosis","volume":"14","author":"Engel","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/bs.acc.2025.01.006_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2024.123115","article-title":"Clinical utility of the lumipulse immunoassay for plasma neurofilament light chain in multiple sclerosis","volume":"463","author":"Nicolella","year":"2024","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/bs.acc.2025.01.006_bib68","unstructured":"Https:\/\/www.Fujirebio.Com\/en\/products-solutions\/lumipulser-g-nfl-blood (accessed October 9, 2024)."},{"key":"10.1016\/bs.acc.2025.01.006_bib69","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/jnc.15757","article-title":"Impact of pre-analytical sample handling factors on plasma biomarkers of alzheimer\u2019s disease","volume":"165","author":"Kurz","year":"2023","journal-title":"J. Neurochem."},{"key":"10.1016\/bs.acc.2025.01.006_bib70","article-title":"Nulisa: a novel proteomic liquid biopsy platform with attomolar sensitivity and high multiplexing","author":"Feng","year":"2023","journal-title":"bioRxiv"},{"key":"10.1016\/bs.acc.2025.01.006_bib71","doi-asserted-by":"crossref","first-page":"7238","DOI":"10.1038\/s41467-023-42834-x","article-title":"Nulisa: a proteomic liquid biopsy platform with attomolar sensitivity and high multiplexing","volume":"14","author":"Feng","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/bs.acc.2025.01.006_bib72","first-page":"1","article-title":"Paper-based lateral flow assay for the point-of-care detection of neurofilament light chain","author":"Zhang","year":"2023","journal-title":"Annu. Int. Conf. IEEE Eng. Med. Biol. Soc. 2023"},{"key":"10.1016\/bs.acc.2025.01.006_bib73","first-page":"18","article-title":"Plasma neurofilament light chains as blood-based biomarkers for early diagnosis of canine cognitive dysfunction syndrome","volume":"24","author":"Wu","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/bs.acc.2025.01.006_bib74","unstructured":"Https:\/\/www.Magqu.Com\/content\/%e2%80%9cmagqu%e2%80%9d-neurofilament-light-imr-reagent (accessed October 9, 2024)."},{"key":"10.1016\/bs.acc.2025.01.006_bib75","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abq5923","article-title":"Proteomics of brain, csf, and plasma identifies molecular signatures for distinguishing sporadic and genetic alzheimer\u2019s disease","volume":"15","author":"Sung","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/bs.acc.2025.01.006_bib76","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/acn3.51996","article-title":"Proteomic signatures of physical, cognitive, and imaging outcomes in multiple sclerosis","volume":"11","author":"Jalaleddini","year":"2024","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/bs.acc.2025.01.006_bib77","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcae132","article-title":"CSF neurofilament light chain profiling and quantitation in neurological diseases","volume":"6","author":"Leckey","year":"2024","journal-title":"Brain Commun."},{"key":"10.1016\/bs.acc.2025.01.006_bib78","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3233\/JAD-220399","article-title":"Comparative analysis of alzheimer\u2019s disease cerebrospinal fluid biomarkers measurement by multiplex somascan platform and immunoassay-based approach","volume":"89","author":"Timsina","year":"2022","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/bs.acc.2025.01.006_bib79","first-page":"12","article-title":"Antibody profiling: kinetics with native biomarkers for diagnostic assay and drug developments","volume":"13","author":"Jucknischke","year":"2023","journal-title":"Biosensors (Basel)"},{"key":"10.1016\/bs.acc.2025.01.006_bib80","doi-asserted-by":"crossref","first-page":"2102341","DOI":"10.1002\/admi.202102341","article-title":"Detection of neurofilament light chain with label-free electrolyte-gated organic field-effect transistors","volume":"9","author":"Solodka","year":"2022","journal-title":"Adv. Mater. Interfaces"},{"key":"10.1016\/bs.acc.2025.01.006_bib81","article-title":"Neurofilament light oligomers in neurodegenerative diseases: quantification by homogeneous immunoassay in cerebrospinal fluid","volume":"5","author":"Francisco","year":"2023","journal-title":"BMJ Neurol. Open"},{"issue":"4","key":"10.1016\/bs.acc.2025.01.006_bib82","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a018309","article-title":"Neurofilaments and neurofilament proteins in health and disease","volume":"9","author":"Yuan","year":"2017","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/bs.acc.2025.01.006_bib83","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/jnr.490300312","article-title":"Characterization of a panel of neurofilament antibodies recognizing n-terminal epitopes","volume":"30","author":"Kaplan","year":"1991","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/bs.acc.2025.01.006_bib84","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcac174","article-title":"Establishment of reference values for plasma neurofilament light based on healthy individuals aged 5-90 years","volume":"4","author":"Simren","year":"2022","journal-title":"Brain Commun."},{"key":"10.1016\/bs.acc.2025.01.006_bib85","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cca.2022.08.017","article-title":"Plasma neurofilament light chain (NfL) reference interval determination in an age-stratified cognitively unimpaired cohort","volume":"535","author":"Bornhorst","year":"2022","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/bs.acc.2025.01.006_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2024.119817","article-title":"Head-to-head comparison of four plasma neurofilament light chain (NfL) immunoassays","volume":"561","author":"Ashrafzadeh-Kian","year":"2024","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/bs.acc.2025.01.006_bib87","unstructured":"Https:\/\/ifcc.Org\/ifcc-scientific-division\/sd-working-groups\/csf-proteins-wg-csf\/ (accessed october 9, 2024)."},{"key":"10.1016\/bs.acc.2025.01.006_bib88","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1515\/cclm-2022-1181","article-title":"Assessing the commutability of candidate reference materials for the harmonization of neurofilament light measurements in blood","volume":"61","author":"Andreasson","year":"2023","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/bs.acc.2025.01.006_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.104970","article-title":"Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management","volume":"101","author":"Freedman","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/bs.acc.2025.01.006_bib90","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1136\/jnnp.64.3.402","article-title":"Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis","volume":"64","author":"Lycke","year":"1998","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/bs.acc.2025.01.006_bib91","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000007032","article-title":"Blood neurofilament light chain as a biomarker of ms disease activity and treatment response","volume":"92","author":"Kuhle","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/bs.acc.2025.01.006_bib92","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.852563","article-title":"Prognostic value of serum neurofilament light chain for disease activity and worsening in patients with relapsing multiple sclerosis: results from the phase 3 asclepios i and ii trials","volume":"13","author":"Ziemssen","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/bs.acc.2025.01.006_bib93","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.3389\/fneur.2018.01037","article-title":"CSF neurofilament light chain levels in primary progressive ms: signs of axonal neurodegeneration","volume":"9","author":"Pawlitzki","year":"2018","journal-title":"Front. Neurol."},{"key":"10.1016\/bs.acc.2025.01.006_bib94","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000200258","article-title":"Blood neurofilament light in progressive multiple sclerosis: post hoc analysis of 2 randomized controlled trials","volume":"98","author":"Leppert","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/bs.acc.2025.01.006_bib95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/NXI.0000000000200052","article-title":"Serum GFAP and NfL levels differentiate subsequent progression and disease activity in patients with progressive multiple sclerosis","volume":"10","author":"Barro","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/bs.acc.2025.01.006_bib96","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1007\/s00415-023-12135-w","article-title":"Baseline serum neurofilament light chain levels differentiate aggressive from benign forms of relapsing-remitting multiple sclerosis: a 20-year follow-up cohort","volume":"271","author":"Arroyo Pereiro","year":"2024","journal-title":"J. Neurol."},{"key":"10.1016\/bs.acc.2025.01.006_bib97","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000009097","article-title":"Blood neurofilament light levels segregate treatment effects in multiple sclerosis","volume":"94","author":"Delcoigne","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/bs.acc.2025.01.006_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104662","article-title":"C. Blood neurofilament light levels predict non-relapsing progression following anti-cd20 therapy in relapsing and primary progressive multiple sclerosis: Findings from the ocrelizumab randomised, double-blind phase 3 clinical trials","volume":"93","author":"Bar-Or","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/bs.acc.2025.01.006_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103590","article-title":"Nfl predicts relapse-free progression in a longitudinal multiple sclerosis cohort study","volume":"72","author":"Uphaus","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/bs.acc.2025.01.006_bib100","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1111\/ene.15321","article-title":"Integrated evaluation of a panel of neurochemical biomarkers to optimize diagnosis and prognosis in amyotrophic lateral sclerosis","volume":"29","author":"Falzone","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/bs.acc.2025.01.006_bib101","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000012632","article-title":"Prediagnostic neurofilament light chain levels in amyotrophic lateral sclerosis","volume":"97","author":"Bjornevik","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/bs.acc.2025.01.006_bib102","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1212\/WNL.0000000000001642","article-title":"Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis","volume":"84","author":"Lu","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/bs.acc.2025.01.006_bib103","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16379","article-title":"Serum neurofilament light chain in distinct phenotypes of amyotrophic lateral sclerosis: a longitudinal, multicenter study","volume":"31","author":"Meyer","year":"2024","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/bs.acc.2025.01.006_bib104","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/mus.27818","article-title":"Neurofilament light-chain response during therapy with antisense oligonucleotide tofersen in sod1-related als: treatment experience in clinical practice","volume":"67","author":"Meyer","year":"2023","journal-title":"Muscle Nerve"},{"key":"10.1016\/bs.acc.2025.01.006_bib105","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/d41573-023-00083-z","article-title":"Nfl makes regulatory debut as neurodegenerative disease biomarker","volume":"22","author":"Mullard","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/bs.acc.2025.01.006_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102495","article-title":"Effects of tofersen treatment in patients with sod1-als in a \u201creal-world\u201d setting \u2013 a 12-month multicenter cohort study from the german early access program","volume":"69","author":"Wiesenfarth","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/bs.acc.2025.01.006_bib107","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","article-title":"Trial of antisense oligonucleotide tofersen for sod1 als","volume":"387","author":"Miller","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2025.01.006_bib108","unstructured":"Https:\/\/www.Fda.Gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-amyotrophic-lateral-sclerosis-associated-mutation-sod1-gene (accessed October 9, 2024)."},{"key":"10.1016\/bs.acc.2025.01.006_bib109","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1007\/s00415-022-11055-5","article-title":"Plasma neurofilament light chain as a biomarker of alzheimer\u2019s disease in subjective cognitive decline and mild cognitive impairment","volume":"269","author":"Giacomucci","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/bs.acc.2025.01.006_bib110","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1212\/WNL.0000000000004667","article-title":"Serum neurofilament light in familial alzheimer disease: a marker of early neurodegeneration","volume":"89","author":"Weston","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/bs.acc.2025.01.006_bib111","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s40035-024-00417-w","article-title":"Considerations for biomarker strategies in clinical trials investigating tau-targeting therapeutics for Alzheimer\u2019s disease","volume":"13","author":"Penny","year":"2024","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/bs.acc.2025.01.006_bib112","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1212\/WNL.54.10.1960","article-title":"Cytoskeleton proteins in csf distinguish frontotemporal dementia from ad","volume":"54","author":"Sjogren","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/bs.acc.2025.01.006_bib113","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1471-2377-13-54","article-title":"Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia","volume":"13","author":"Landqvist Waldo","year":"2013","journal-title":"BMC Neurol."},{"key":"10.1016\/bs.acc.2025.01.006_bib114","article-title":"Comprehensive cross-sectional and longitudinal analyses of plasma neurofilament light across ftd spectrum disorders","volume":"3","author":"Gendron","year":"2022","journal-title":"Cell Rep. Med."},{"key":"10.1016\/bs.acc.2025.01.006_bib115","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000010084","article-title":"NfL as a biomarker for neurodegeneration and survival in Parkinson disease","volume":"95","author":"Backstrom","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/bs.acc.2025.01.006_bib116","doi-asserted-by":"crossref","first-page":"9307","DOI":"10.1212\/WNL.0000000000003680","article-title":"Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorder","volume":"88","author":"Hansson","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/bs.acc.2025.01.006_bib117","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S1474-4422(17)30124-2","article-title":"Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington\u2019s disease: a retrospective cohort analysis","volume":"16","author":"Byrne","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/bs.acc.2025.01.006_bib118","doi-asserted-by":"crossref","first-page":"913","DOI":"10.3233\/JAD-210342","article-title":"Plasma neurofilament light chain predicts cognitive progression in prodromal and clinical dementia with lewy bodies","volume":"82","author":"Pilotto","year":"2021","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/bs.acc.2025.01.006_bib119","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1093\/brain\/awac253","article-title":"Neurofilament light levels predict clinical progression and death in multiple system atrophy","volume":"145","author":"Chelban","year":"2022","journal-title":"Brain"},{"key":"10.1016\/bs.acc.2025.01.006_bib120","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/acn3.290","article-title":"Plasma neurofilament light chain predicts progression in progressive supranuclear palsy","volume":"3","author":"Rojas","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/bs.acc.2025.01.006_bib121","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0152347","article-title":"The Swiss multiple sclerosis cohort-study (smsc): a prospective swiss wide investigation of key phases in disease evolution and new treatment options","volume":"11","author":"Disanto","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/bs.acc.2025.01.006_bib122","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1111\/ene.15009","article-title":"Ozanimod Study, Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: post hoc analysis of phase 3 ozanimod trials","volume":"28","author":"Harris","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/bs.acc.2025.01.006_bib123","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/alz.12422","article-title":"Alzheimer\u2019s Disease Neuroimaging, Using the alzheimer\u2019s disease neuroimaging initiative to improve early detection, diagnosis, and treatment of alzheimer\u2019s disease","volume":"18","author":"Veitch","year":"2022","journal-title":"Alzheimers Dement."},{"key":"10.1016\/bs.acc.2025.01.006_bib124","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/s41591-021-01369-8","article-title":"Dominantly Inherited Alzheimer Network-Trials, A trial of gantenerumab or solanezumab in dominantly inherited alzheimer\u2019s disease","volume":"27","author":"Salloway","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/bs.acc.2025.01.006_bib125","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1111\/ene.15258","article-title":"Diagnostic accuracy of cerebrospinal fluid biomarkers for the differential diagnosis of sporadic Creutzfeldt-Jakob disease: a (network) meta-analysis","volume":"29","author":"Rubsamen","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/bs.acc.2025.01.006_bib126","doi-asserted-by":"crossref","first-page":"5955","DOI":"10.1038\/s41380-021-01045-w","article-title":"Evaluation of plasma tau and neurofilament light chain biomarkers in a 12-year clinical cohort of human prion diseases","volume":"26","author":"Thompson","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/bs.acc.2025.01.006_bib127","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1007\/s00415-019-09389-8","article-title":"NfL is a marker of treatment response in children with sma treated with nusinersen","volume":"266","author":"Olsson","year":"2019","journal-title":"J. Neurol."},{"key":"10.1016\/bs.acc.2025.01.006_bib128","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000030849","article-title":"Serum neurofilament light chain levels are correlated with the infarct volume in patients with acute ischemic stroke","volume":"101","author":"Ahn","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/bs.acc.2025.01.006_bib129","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3390\/cells10061537","article-title":"Neurofilament light chain (NfL) in blood-a biomarker predicting unfavourable outcome in the acute phase and improvement in the late phase after stroke","volume":"10","author":"Pekny","year":"2021","journal-title":"Cells"},{"key":"10.1016\/bs.acc.2025.01.006_bib130","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abg9922","article-title":"Axonal marker neurofilament light predicts long-term outcomes and progressive neurodegeneration after traumatic brain injury","volume":"13","author":"Graham","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/bs.acc.2025.01.006_bib131","article-title":"Neurofilament light chain and s100b serum levels are associated with disease severity and outcome in patients with aneurysmal subarachnoid hemorrhage","volume":"13","author":"Zhou","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/bs.acc.2025.01.006_bib132","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1515\/cclm-2019-0532","article-title":"Plasma neurofilament light chain is associated with mortality after spontaneous intracerebral hemorrhage","volume":"58","author":"Hviid","year":"2020","journal-title":"Clin. Chem. Lab Med."},{"key":"10.1016\/bs.acc.2025.01.006_bib133","doi-asserted-by":"crossref","first-page":"23727","DOI":"10.18632\/aging.103927","article-title":"Neurofilament light chain predicts risk of recurrence in cerebral amyloid angiopathy-related intracerebral hemorrhage","volume":"12","author":"Cheng","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/bs.acc.2025.01.006_bib134","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12974-021-02138-7","article-title":"Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder","volume":"18","author":"Schindler","year":"2021","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/bs.acc.2025.01.006_bib135","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1007\/s00415-019-09306-z","article-title":"Serum and CSF neurofilament light chain levels in antibody-mediated encephalitis","volume":"266","author":"Mariotto","year":"2019","journal-title":"J. Neurol."},{"key":"10.1016\/bs.acc.2025.01.006_bib136","doi-asserted-by":"crossref","DOI":"10.1038\/s41380-024-02554-0","article-title":"Long COVID: plasma levels of neurofilament light chain in mild COVID-19 patients with neurocognitive symptoms","author":"Gutman","year":"2024","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/bs.acc.2025.01.006_bib137","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00125-022-05846-8","article-title":"Serum neurofilament light chain: a novel biomarker for early diabetic sensorimotor polyneuropathy","volume":"66","author":"Maalmi","year":"2023","journal-title":"Diabetologia"},{"key":"10.1016\/bs.acc.2025.01.006_bib138","doi-asserted-by":"crossref","first-page":"986","DOI":"10.2337\/dc23-2208","article-title":"Longitudinal change in serum neurofilament light chain in type 2 diabetes and early diabetic polyneuropathy: addition-denmark","volume":"47","author":"Maatta","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/bs.acc.2025.01.006_bib139","doi-asserted-by":"crossref","DOI":"10.1038\/s41380-024-02524-6","article-title":"Introducing neurofilament light chain measure in psychiatry: current evidence, opportunities, and pitfalls","author":"Bavato","year":"2024","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/bs.acc.2025.01.006_bib140","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jpsychires.2021.05.072","article-title":"Altered neuroaxonal integrity in schizophrenia and major depressive disorder assessed with neurofilament light chain in serum","volume":"140","author":"Bavato","year":"2021","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/bs.acc.2025.01.006_bib141","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1001\/jamaneurol.2021.3589","article-title":"Changes in blood biomarkers of brain injury and degeneration following long-duration spaceflight","volume":"78","author":"Zu-Eulenburg","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/bs.acc.2025.01.006_bib142","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1007\/s12035-020-01951-0","article-title":"Plasma neurofilament light chain as a translational biomarker of aging and neurodegeneration in dogs","volume":"57","author":"Panek","year":"2020","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/bs.acc.2025.01.006_bib143","article-title":"Neurofilament light chain: a candidate biomarker of perioperative stroke","volume":"14","author":"Zhang","year":"2022","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/bs.acc.2025.01.006_bib144","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.3233\/JAD-191165","article-title":"Cardiac surgery is associated with biomarker evidence of neuronal damage","volume":"74","author":"Alifier","year":"2020","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/bs.acc.2025.01.006_bib145","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s12974-021-02254-4","article-title":"Plasma neurofilament light chain level predicts outcomes in stroke patients receiving endovascular thrombectomy","volume":"18","author":"Chen","year":"2021","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/bs.acc.2025.01.006_bib146","doi-asserted-by":"crossref","first-page":"241","DOI":"10.5507\/bp.2019.043","article-title":"A case series on the value of tau and neurofilament protein levels to predict and detect delirium in cardiac surgery patients","volume":"163","author":"Saller","year":"2019","journal-title":"Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub."},{"key":"10.1016\/bs.acc.2025.01.006_bib147","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1001\/jamaoncol.2022.3738","article-title":"Assessment of pretreatment and posttreatment evolution of neurofilament light chain levels in patients who develop immune effector cell-associated neurotoxicity syndrome","volume":"8","author":"Butt","year":"2022","journal-title":"JAMA Oncol."},{"key":"10.1016\/bs.acc.2025.01.006_bib148","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1182\/bloodadvances.2021006144","article-title":"Neurofilament light chain serum levels correlate with the severity of neurotoxicity after car t-cell treatment","volume":"6","author":"Schoeberl","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/bs.acc.2025.01.006_bib149","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104955","article-title":"Concentrations of s100b and neurofilament light chain in blood as biomarkers for checkpoint inhibitor-induced cns inflammation","volume":"100","author":"Bjursten","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/bs.acc.2025.01.006_bib150","article-title":"Diagnostic and prognostic biomarkers in immune checkpoint inhibitor-related encephalitis: a retrospective cohort study","volume":"44","author":"Farina","year":"2024","journal-title":"Lancet Reg. Health Eur."},{"key":"10.1016\/bs.acc.2025.01.006_bib151","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/jns.12493","article-title":"Prospectively assessing serum neurofilament light chain levels as a biomarker of paclitaxel-induced peripheral neurotoxicity in breast cancer patients","volume":"27","author":"Karteri","year":"2022","journal-title":"J. Peripher. Nerv. Syst."},{"key":"10.1016\/bs.acc.2025.01.006_bib152","article-title":"Blood neurofilament light chain as a biomarker for monitoring and predicting paclitaxel-induced peripheral neuropathy in patients with gynecological cancers","volume":"12","author":"Kim","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/bs.acc.2025.01.006_bib153","doi-asserted-by":"crossref","first-page":"17368","DOI":"10.1038\/s41598-018-35766-w","article-title":"Levels of plasma neurofilament light chain and cognitive function in patients with alzheimer or parkinson disease","volume":"8","author":"Lin","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/bs.acc.2025.01.006_bib154","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1177\/1352458519840757","article-title":"Longitudinal analysis of serum neurofilament light chain: a potential therapeutic monitoring biomarker for multiple sclerosis","volume":"26","author":"Hyun","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/bs.acc.2025.01.006_bib155","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41582-019-0265-2","article-title":"Neurofilament light chain \u2013 new potential for prediction and prognosis","volume":"15","author":"Fyfe","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/bs.acc.2025.01.006_bib156","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s10654-024-01131-7","article-title":"Serum neurofilament light chain as a prognostic marker of all-cause mortality in a national sample of us adults","volume":"39","author":"Beydoun","year":"2024","journal-title":"Eur. J. Epidemiol."},{"key":"10.1016\/bs.acc.2025.01.006_bib157","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s12916-022-02425-x","article-title":"Plasma neurofilament light and its association with all-cause mortality risk among urban middle-aged men and women","volume":"20","author":"Beydoun","year":"2022","journal-title":"BMC Med."},{"key":"10.1016\/bs.acc.2025.01.006_bib158","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104146","article-title":"Serum neurofilament light levels are predictive of all-cause mortality in late middle-aged individuals","volume":"82","author":"Nguyen","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/bs.acc.2025.01.006_bib159","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12916-021-01915-8","article-title":"Serum neurofilament light and tau as prognostic markers for all-cause mortality in the elderly general population-an analysis from the memo study","volume":"19","author":"Rubsamen","year":"2021","journal-title":"BMC Med."},{"key":"10.1016\/bs.acc.2025.01.006_bib160","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(24)01296-0","article-title":"Dementia prevention, intervention, and care: 2024 report of the lancet standing commission","volume":"404","author":"Livingston","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/bs.acc.2025.01.006_bib161","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/jnc.15682","article-title":"The 2022 Lady Estelle Wolfson Lectureship on Neurofilaments","volume":"163","author":"Petzold","year":"2022","journal-title":"J. Neurochem."},{"key":"10.1016\/bs.acc.2025.01.006_bib162","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1002\/acn3.52054","article-title":"Non-neurological factors associated with serum neurofilament levels in the united states population","volume":"11","author":"Ramanathan","year":"2024","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/bs.acc.2025.01.006_bib163","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1097\/ALN.0000000000004922","article-title":"Serum neurofilament light and postoperative delirium in cardiac surgery: a preplanned secondary analysis of a prospective observational study","volume":"140","author":"Khalifa","year":"2024","journal-title":"Anesthesiology"},{"key":"10.1016\/bs.acc.2025.01.006_bib164","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.bja.2023.10.043","article-title":"Association of perioperative plasma concentration of neurofilament light with delirium after cardiac surgery: a nested observational study","volume":"132","author":"Brown","year":"2024","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/bs.acc.2025.01.006_bib165","doi-asserted-by":"crossref","first-page":"1186061","DOI":"10.3389\/fped.2023.1186061","article-title":"Perioperative brain injury marker concentrations in neonatal open-heart surgery: a prospective observational study","volume":"11","author":"Jungner","year":"2023","journal-title":"Front. Pediatr."},{"key":"10.1016\/bs.acc.2025.01.006_bib166","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/s41586-023-06802-1","article-title":"Organ aging signatures in the plasma proteome track health and disease","volume":"624","author":"Oh","year":"2023","journal-title":"Nature"},{"key":"10.1016\/bs.acc.2025.01.006_bib167","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41576-022-00511-7","article-title":"Measuring biological age using omics data","volume":"23","author":"Rutledge","year":"2022","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/bs.acc.2025.01.006_bib168","doi-asserted-by":"crossref","first-page":"66417","DOI":"10.1007\/s11356-023-26943-0","article-title":"Urinary di-(2-ethylhexyl) phthalate metabolites are independently related to serum neurofilament light chain, a biomarker of neurological diseases, in adults: Results from nhanes 2013-2014","volume":"30","author":"Yang","year":"2023","journal-title":"Environ. Sci. Pollut. Res. Int."},{"key":"10.1016\/bs.acc.2025.01.006_bib169","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1186\/s12889-024-17811-8","article-title":"Correlation analysis between smoke exposure and serum neurofilament light chain in adults: a cross-sectional study","volume":"24","author":"Zhu","year":"2024","journal-title":"BMC Public Health"},{"key":"10.1016\/bs.acc.2025.01.006_bib171","unstructured":"Neurofilament light chain (NfL) for atellica im analyzer: Instructions for use, 11209406_en rev. 01, 2024\u201304 (siemens healthcare diagnstics inc., Tarrytown, NY, USA) (accessed October 9, 2024)."},{"key":"10.1016\/bs.acc.2025.01.006_bib172","unstructured":"Https:\/\/www.Labcorp.Com\/assets-media\/2772 accessed october 9, 2024."},{"issue":"Suppl. 1","key":"10.1016\/bs.acc.2025.01.006_bib173","article-title":"A-103 analytical performance evaluation of plasma NfL in a clinical diagnostic laboratory","volume":"70","author":"Frykman","year":"2024","journal-title":"Clin. Chem."},{"key":"10.1016\/bs.acc.2025.01.006_bib174","unstructured":"Https:\/\/www.Fujirebio.Com\/en\/insights\/neurodegenerative-diseases\/scientific-poster-analytical-performance-of-the-lumipulser-g (accessed October 9, 2024)."}],"container-title":["Advances in Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065242325000174?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065242325000174?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T05:31:55Z","timestamp":1743744715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065242325000174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9780443429934"],"references-count":173,"URL":"https:\/\/doi.org\/10.1016\/bs.acc.2025.01.006","relation":{},"ISSN":["0065-2423"],"issn-type":[{"value":"0065-2423","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}